To test this hypothesis, we conducted a phase 1b, biomarker-driven trial, evaluating DNMT and HDAC inhibitors alone or in combination in sensitizing MMRp CRC to anti-PD1 therapy. The gene discussed is DNMT1; the disease is colorectal carcinoma.